Clinical Trials

About Clinical Trials
Clinical trial participation is an individual, and important, decision. There are many advantages to participating in a trial, including care from medical teams experienced with the disease and the opportunity to try a new medication long before it is approved by the Food and Drug Administration to treat an indicated condition. If you choose to participate in a clinical trial, you have the right to understand fully what is expected of you, what the trial will involve and the potential risks to your health. You also have the right to withdraw your consent to participate at any time. For more resources about trial participation and informed consent, please see the resources available from the U.S. Department of Health and Human Services.

Please note: Trials that are recruiting patients with eosinophil-associated disease and a search engine that can help match you to an enrolling trial appear below.  Neither the list nor search engine results are considered exhaustive. The clinical trials listed here were verified as open and enrolling at the time the post was made, and are monitored periodically to ensure that the trial is still accepting participants. If a trial is no longer accepting patients, APFED may not be notified. If you find registration has closed for a trial that is still listed on this page, please notify mail@apfed.org.

Trials of Interest:

Eosinophilic Esophagitis

Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects With Eosinophilic Esophagitis

Ages: 15 Years and older
Study Reference: NCT04281108
Study Type:  Interventional
Location: Multiple locations in U.S.
Learn more

A Study of Benralizumab in Patients with Eosinophilic Esophagitis (MESSINA)

Ages: 12-65 Years
Study Reference: NCT02599558
Study Type:  Interventional NCT02599558
Location: Multiple locations, International
Learn more

VOYAGE Study

Ages: 18-65
Study type: Interventional
Location: Multiple

Learn more
Download flyer

Contact Information:
Contact: Arena Patient Center
Phone: (844)-302-1232
Email: arena@patientwing.com

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis (KRYPTOS)

Allakos

Ages: 12-80
Study Reference: NCT04322708
Study type: Interventional
Location: Multiple
Learn more
Download flyer

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Ages: 12 and older
Study Reference: NCT03633617
Study type: Interventional
Location: Multiple
Learn more

Cytosponge and Dietary Therapy in EoE

Ages:  18-70
Study Reference: NCT02599558
Study Type:  Interventional
Location:  Minnesota
Learn more

Cytosponge Protocol

Ages: 18-65
Study Reference: NCT01585103
Study type: Interventional
Location: Mayo Clinic, Rochester MN
Learn more

Phase 2 Study of Esophageal String Test in Eosinophilic Esophagitis

Ages: 7-65
Study Reference: NCT02008903
Study type: Observational
Location: Children’s Hospital Colorado (Aurora, CO); Lurie Children’s Hospital (Chicago, IL); Northwestern University (Chicago, IL)
Learn more

Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools

Ages: 5-80
Study Reference: NCT02453126
Study type: Observational
Location: Mayo Clinic, Rochester, MI
Learn more

Natural History and Genetics of Food Allergy and Related Conditions

Ages: 2-99
Study Reference: NCT02504853
Study Type: Observational
Location: Maryland
Learn more

Protocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic Esophagitis

Ages: 18-80
Study Reference: NCT02434705
Study type: Interventional
Location: Mayo Clinic, Rochester, MI
Learn more

Eosinophilic Gastritis/Eosinophilic Gastroenteritis/Eosinophilic Duodenitis

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) (ENIGMA 2)

Allakos

Ages: 18-80
Study Reference: NCT04322604
Study type: Interventional
Location: Multiple locations in the U.S.
Learn more
Download the flyer

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

Ages: consent obtained for ages 11+
Study Reference: NCT00267501
Study type: Observational
Location: Cincinnati, OH
Learn more

Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)

A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in patients receiving Standard of Care Therapy

Ages: 18 and older
Study Reference: NCT04157348
Study type: Interventional
Location: Multiple, including international
Learn more

Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes

Ages: 0-20
Study Reference: NCT02006134
Study type: Observational
Location: Multiple, including international
Learn more

High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome

Ages: 16-60
Study Reference: NCT00278512
Study type: Interventional
Location: Chicago, IL
Learn more

Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)

Ages: any age
Study Reference: NCT00315380
Study type: Observational
Location: Multiple, including Canada
Learn more

Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)

Ages: 18+
Study Reference: NCT01862068
Study Type: Observational
Location: France
Learn more

Vasculitis Pregnancy Registry

Ages: 18-50 Female
Study Reference: NCT02593565
Study Type:  Observational/Patient Registry
Location:  Online Registry
Learn more

VCRC Genetic Repository One-Time DNA Protocol

Ages: 7+
Study Reference: NCT01241305
Study type: Observational
Location: Multiple, including Canada
Learn more

Hypereosinophilic Syndromes

A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON)

Ages: 12 and older
Study Reference: NCT04191304
Study type: Interventional
Location: Multiple
Learn more
Related webpage (for sharing)

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

Ages: 18-65
Study Reference: NCT02130882
Study type: Interventional
Location: Bethesda, MD
Learn more

A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects With Hypereosinophilic Syndrome

Ages: 12+
Study Reference: NCT00244686
Study type: Interventional
Location: Multiple, including international sites
Learn more

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

Ages: any age
Study Reference: NCT00091871
Study type: Observational
Location: Bethesda, MD
Learn more

Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

Ages: 7+
Study Reference: NCT01524536
Study type: Interventional
Location: Bethesda, MD
Learn more

Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients With Myeloproliferative and/or Steroid-Refractory Hypereosinophilic Syndrome

Ages: 2+
Study Reference: NCT00044304
Study type: Interventional
Location: Bethesda, MD
Learn more

SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

Ages: 18+
Study Reference: NCT02268253
Study Type: Interventional
Location: Multiple US/Canada
Learn more 

Eosinophilic Fasciitis

Coordination of Rare Diseases at Sanford

Ages: not specified
Study Reference: NCT01793168
Study type: Observational
Location: Sioux Falls, SD
Learn more